WHIM Syndrome: Symptoms, Treatment, and Global Market Outlook (2024-2032)
29 October 2024
The global market for WHIM syndrome treatments is projected to grow at a CAGR of 4.61% from 2024 to 2032, reaching USD 13.2 million by 2032. North America leads the market with a 47.42% share.
WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) is a rare genetic disorder caused by mutations in the CXCR4 gene. These mutations lead to abnormal immune cell behavior, resulting in a weakened immune system. Individuals with WHIM syndrome experience recurrent bacterial infections, low levels of antibodies (hypogammaglobulinemia), and myelokathexis, where mature neutrophils (a type of white blood cell) are trapped in the bone marrow, leading to neutropenia. A hallmark symptom is the development of persistent warts caused by human papillomavirus (HPV), which can sometimes lead to cancer.
